Phase II study of capecitabine, irinotecan, and celecoxib in advanced colorectal cancer.

被引：0
|
作者：
El-Rayes, BF
Shields, AF
Vaishampayan, U
Heilbrun, L
Bekaii-Saab, T
Zalupski, MM
Philip, PA
机构：
[1] Karmanos Canc Inst, Detroit, MI USA
[2] Ohio State Univ, Columbus, OH 43210 USA
[3] Univ Michigan, Ann Arbor, MI 48109 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2004年 / 22卷 / 14期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3766
引用
收藏
页码：310S / 310S
页数：1
相关论文
共 50 条
  • [31] Phase II, prospective, open-label study of a weekly schedule of irinotecan in patients with advanced colorectal cancer.
    Casinello, J
    Dorta, J
    Aguiar, J
    Pérez-Carrión, J
    Castellanos, J
    Valladares, J
    Sevilla, J
    Belón, J
    Fernández, J
    Casal, J
    ANNALS OF ONCOLOGY, 2000, 11 : 46 - 46
  • [32] Phase I/II study of oral uracil/tegafur (UFT®), leucovorin and irinotecan in patients with advanced colorectal cancer.
    Hill, M
    Mackay, H
    Cunningham, D
    Glasspool, R
    Price, T
    Campbell, S
    Massey, A
    Bailey, S
    Martin, C
    Twelves, C
    ANNALS OF ONCOLOGY, 2000, 11 : 45 - 45
  • [33] Phase II study of docetaxel, cisplatin, and irinotecan in advanced esophageal and gastric cancer.
    Enzinger, PC
    Clark, J
    Ryan, D
    Meyerhardt, J
    Kulke, M
    Fidias, P
    Earle, C
    Vincitore, M
    Michelini, A
    Fuchs, C
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 323S - 323S
  • [34] A Phase II Study of Celecoxib With Irinotecan, 5-Fluorouracil, and Leucovorin in Patients With Previously Untreated Advanced or Metastatic Colorectal Cancer
    Chen, Emerson Y.
    Blanke, Charles D.
    Haller, Daniel G.
    Benson, Al B.
    Dragovich, Tomislav
    Lenz, Heinz-Josef
    Robles, Carlos
    Li, Hong
    Mori, Motomi
    Mattek, Nora
    Sanborn, Rachel E.
    Lopez, Charles D.
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2018, 41 (12): : 1193 - 1198
  • [35] Phase II study of gemcitabine, capecitabine and cisplatin in patients with advanced pancreatic cancer.
    Chang, HM
    Kim, TW
    Ahn, JH
    Ryu, MH
    Lee, JS
    Kim, WK
    Kang, YK
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 368S - 368S
  • [36] A phase II study of capecitabine, irinotecan, and bevacizumab in patients with previously untreated metastatic colorectal cancer
    Daniel J. Renouf
    Stephen Welch
    Malcolm J. Moore
    Monika K. Krzyzanowska
    Jennifer Knox
    Ronald Feld
    Geoffrey Liu
    Helen MacKay
    Jennifer Petronis
    Lisa Wang
    Eric Chen
    Cancer Chemotherapy and Pharmacology, 2012, 69 : 1339 - 1344
  • [37] A phase II study of capecitabine, irinotecan, and bevacizumab in patients with previously untreated metastatic colorectal cancer
    Renouf, Daniel J.
    Welch, Stephen
    Moore, Malcolm J.
    Krzyzanowska, Monika K.
    Knox, Jennifer
    Feld, Ronald
    Liu, Geoffrey
    MacKay, Helen
    Petronis, Jennifer
    Wang, Lisa
    Chen, Eric
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2012, 69 (05) : 1339 - 1344
  • [38] Phase II trial of capecitabine and irinotecan in combination with concurrent radiotherapy for neoadjuvant treatment of locally advanced rectal cancer.
    Willeke, F
    Tiefenbacher, U
    Hochhaus, A
    Wenz, F
    von Gerstenbergk, B
    Gnad-Vogt, U
    Horisberger, K
    Post, S
    Hofheinz, R
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 268S - 268S
  • [39] Phase I/II study of irinotecan and UFT for advanced or metastatic colorectal cancer
    Mibu, R.
    Tanaka, S.
    Futami, K.
    Shimada, K.
    Hotokezaka, M.
    Nakahara, S.
    Ichimiya, H.
    Kido, H.
    Hirano, Y.
    Kashiwagi, T.
    Eguchi, T.
    Mitsuki, K.
    Mizumoto, K.
    Tanaka, M.
    ANTICANCER RESEARCH, 2007, 27 (4C) : 2673 - 2677
  • [40] Phase II Trial of Gemcitabine, Irinotecan, and Celecoxib in Patients With Advanced Pancreatic Cancer
    Lipton, Allan
    Campbell-Baird, Cynthia
    Witters, Lois
    Harvey, Harold
    Ali, Suhail
    JOURNAL OF CLINICAL GASTROENTEROLOGY, 2010, 44 (04) : 286 - 288
12345